Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Studies suggest BTK inhibitors and hormone therapy might lessen disease severity and speed recovery.
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
The FDA granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.